Report Content
Chapter 1 Methodology & Scope
1.1 Market scope & definitions
1.2 Research design
1.2.1 Research approach
1.2.2 Data collection methods
1.3 Base estimates & calculations
1.3.1 Base year calculation
1.3.2 Key trends for market estimation
1.4 Forecast model
1.5 Primary research and validation
1.5.1 Primary sources
1.5.2 Data mining sources
Chapter 2 Executive Summary
2.1 Industry 3600 synopsis
Chapter 3 Industry Insights
3.1 Industry ecosystem analysis
3.2 Industry impact forces
3.2.1 Growth drivers
3.2.1.1 Rising incidence of cancer
3.2.1.2 Growing approvals for oncolytic therapy for treating rare cancers
3.2.1.3 Increasing investments for developing new oncolytic virotherapies
3.2.1.4 Growing focus towards combination therapies
3.2.2 Industry pitfalls & challenges
3.2.2.1 Issues related to scaling-up of clinical-grade oncolytic viruses
3.2.2.2 Requirement for high investments in clinical research
3.3 Growth potential analysis
3.4 Future market trends
3.5 Regulatory landscape
3.6 Porter's analysis
3.7 PESTEL analysis
Chapter 4 Competitive Landscape, 2023
4.1 Introduction
4.2 Company matrix analysis
4.3 Competitive positioning matrix
4.4 Strategy dashboard
Chapter 5 Market Estimates and Forecast, By Virus Type, 2021 – 2032 ($ Mn)
5.1 Key trends
5.2 Genetically engineered oncolytic viruses
5.2.1 Adenovirus
5.2.2 Herpes simplex virus
5.2.3 Vaccinia virus
5.3 Oncolytic wild-type viruses
5.3.1 Reovirus
5.3.2 Vesicular stomatitis virus
5.3.3 Newcastle disease virus
Chapter 6 Market Estimates and Forecast, By Application, 2021 – 2032 ($ Mn)
6.1 Key trends
6.2 Solid tumors
6.2.1 Breast cancer
6.2.2 Prostate cancer
6.2.3 Lung cancer
6.2.4 Glioblastoma
6.3 Melanoma
6.3.1 Leukemia
6.3.2 Lymphoma
6.3.3 Myeloma
6.3.4 Hematological malignancies
Chapter 7 Market Estimates and Forecast, By End-user, 2021 – 2032 ($ Mn)
7.1 Key trends
7.2 Hospitals
7.3 Specialty clinics
7.4 Cancer research institutes
Chapter 8 Market Estimates and Forecast, By Region, 2021 – 2032 ($ Mn)
8.1 Key trends
8.2 North America
8.2.1 U.S.
8.2.2 Canada
8.3 Europe
8.3.1 Germany
8.3.2 UK
8.3.3 France
8.3.4 Spain
8.3.5 Italy
8.3.6 Netherlands
8.3.7 Rest of Europe
8.4 Asia Pacific
8.4.1 China
8.4.2 Japan
8.4.3 India
8.4.4 Australia
8.4.5 South Korea
8.4.6 Rest of Asia Pacific
8.5 Latin America
8.5.1 Brazil
8.5.2 Mexico
8.5.3 Rest of Latin America
8.6 Middle East and Africa
8.6.1 South Africa
8.6.2 Saudi Arabia
8.6.3 UAE
8.6.4 Rest of Middle East and Africa
Chapter 9 Company Profiles
9.1 Amgen Inc.
9.2 BioVex, Inc.
9.3 Circio Holding ASA
9.4 Daiichi Sankyo Company
9.5 DNAtrix
9.6 Lokon Pharma AB
9.7 Medigene AG
9.8 Oncolytics Biotech Inc.
9.9 PsiOxus Therapeutics
9.10 Shanghai Sunway Biotech Co., Ltd.
9.11 SillaJen, Inc.
9.12 Sorrento Therapeutics
9.13 Theriva Biologics
9.14 Transgene SA
9.15 Virogin Biotech
